by 
The anti-neprilysin market comprises drugs that inhibit neprilysin, a zinc metallopeptidase enzyme expressed mainly in kidney and lung tissues. Neprilysin is involved in the degradation of several peptide hormones including natriuretic peptides, enkephalins, and substance P. Inhibiting neprilysin leads to increased levels of these endogenous peptides, which exert favorable cardiovascular and renal effects. Drugs combining neprilysin inhibitors with other classes such as angiotensin receptor blockers are used for the treatment of heart failure. Sacubitril/valsartan a first-in-class drug in this category was the first to demonstrate reduced cardiovascular mortality compared to ACE inhibitors. Sacubitril/valsartan along with expanding clinical evidence and new pipeline molecules are driving increased adoption of neprilysin inhibitors drugs globally.
The global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Growing adoption of neprilysin inhibitors drugs: Sacubitril/valsartan was the first neprilysin inhibitor drug demonstrating reduced cardiovascular mortality in heart failure patients compared to ACE inhibitors. Since its approval in 2015, sacubitril/valsartan witnessed rapid adoption globally supported by clinical guidelines recommending its use for specific heart failure patients. Rising awareness about therapeutic advantages of neprilysin inhibitors combined with expanding indications is expected to drive increased adoption further over the forecast period.
Increasing heart failure disease burden: Heart failure prevalence is rising globally due to aging population and better survival of patients post myocardial infarction. It is a major cause of hospitalization globally posing substantial healthcare burden. Unmet needs in heart failure management are driving research into new targets like neprilysin inhibition. Increasing heart failure patient pool worldwide presents opportunities for neprilysin inhibitor drugs over the coming years.
Segment Analysis
The global anti-neprilysin market is dominated by two drug types: Candersartan/Neprilysin/Amlodipine, a combination of Candersartan, Neprilysin inhibitor, and Amlodipine; and Sacubitril/Neprilysin inhibitor. Sacubitril/Neprilysin inhibitor is the dominating segment as it is the first approved neprilysin inhibitor drug to treat heart failure. It works by inhibiting neprilysin and enhancing the effects of natriuretic peptides. The drug has shown significant improvement in cardiac function and reduction in cardiovascular mortality and hospitalization for heart failure.
PEST Analysis
Political: The anti-neprilysin market is regulated by various regulatory bodies that approve new drug innovations and set guidelines for drug testing and marketing approval procedures. Stringent regulations ensure drug quality and safety.
Economic: As heart failure prevalence increases with ageing population globally, healthcare spending on treatment is also rising, benefitting market players. However, pricing pressures and healthcare cost containment measures could impact market growth.
Social: Rising awareness about new treatment options and willingness to pay for premium drugs to manage chronic conditions like heart failure drives the market. However, social stigmas related to certain conditions may limit full realization of treatment benefits.
Technological: Advancements in drug delivery systems and combination therapies integrating neprilysin inhibition are expanding treatment scope. Ongoing R&D on novel neprilysin inhibitors and biomarker-guided approaches could further augment the market.
Key Takeaways
The global anti-neprilysin market is expected to witness high growth supported by an aging population prone to heart disease, rising healthcare expenditure in major markets, and availability of latest drug therapies combining neprilysin inhibition. The market size was estimated to be US$ 1,263.3 Mn in 2023 and is forecast to reach US$ 1,828.2 Mn by 2030, growing at a CAGR of 4.6% during the forecast period.
Regional analysis: North America currently dominates the market and is expected to continue its lead, supported by availability of advanced healthcare facilities and higher adoption of novel drugs. However, Asia Pacific is poised to witness fastest growth over the forecast period supported by rising healthcare infrastructure, surge in discretionary spending on healthcare, and availability of low-cost generic versions ofkey drugs in major Asian countries.
Key players: Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. Novartis AG dominates with its product Entresto, a combination of Sacubitril and Valsartan indicated for heart failure. Other key players are focused on developing novel neprilysin inhibitors and biomarker-based formulations for optimized patient outcomes.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
